Imatinib, 98%, an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity

Name: Imatinib, 98%, an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity | 152459-95-5
Brand: J&K Chemical
SKU: JK993508_5_G
Price: 9.69 USD
Availability: OutOfStock

Cat. No JK993508_5_G

Vendor: J&K Chemical

Product Information

Product Name

Imatinib, 98%, an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity

Brand Name

J&K

Product Number

993508

CAS

152459-95-5

Molecular Formula

C29H31N7O

Molecular Weight

493.61

SDS Document

View/Download

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

5291

IUPAC Name

4-(4-methylpiperazin-1-yl)methyl-N-4-methyl-3-(4-pyridin-3-ylpyrimidin-2-yl)aminophenylbenzamide

InChI Key

KTUFNOKKBVMGRW-UHFFFAOYSA-N

SMILES

CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5

Safety Information

Precautionary Statement

P262

References Data Source From Pubchem

[Lichen nitidus in a young man on antiepileptic therapy]

Publication Name: Dermatologie (Heidelberg, Germany)

Publication Date: 2026-05

DOI: 10.1007/s00105-025-05612-y

[Sarcomas : Clinical introduction]

Publication Name: Radiologie (Heidelberg, Germany)

Publication Date: 2026-05

DOI: 10.1007/s00117-026-01581-y

Alcohol consumption in cancer patients receiving psycho-oncologic care analysis of socio-demographic, health-related and cancer-related factors

Publication Name: Journal of cancer survivorship : research and practice

Publication Date: 2026-04

DOI: 10.1007/s11764-024-01673-5

JAK-STAT signaling: molecular mechanism and targeted treatment in dento-maxillofacial abnormalities

Publication Name: International Journal of Oral Science

Publication Date: 2026-03-05

DOI: 10.1038/s41368-025-00399-z

Status of Clinical Care of Duchenne Muscular Dystrophy: Global Perspective and Situation in India

Publication Name: Indian Journal of Pediatrics

Publication Date: 2026-03-04

DOI: 10.1007/s12098-025-05975-z

Imatinib, 98%, an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity

Product Information

General Information

Safety Information

References Data Source From Pubchem

[Lichen nitidus in a young man on antiepileptic therapy]

[Sarcomas : Clinical introduction]

Alcohol consumption in cancer patients receiving psycho-oncologic care analysis of socio-demographic, health-related and cancer-related factors

JAK-STAT signaling: molecular mechanism and targeted treatment in dento-maxillofacial abnormalities

Status of Clinical Care of Duchenne Muscular Dystrophy: Global Perspective and Situation in India